Patients with locally advanced gastric cancers saw complete response rates of 18.3% from camrelizumab and rivoceranib plus ...

CAN-2409 resulted in disease-free survival improvements for patients with high-risk, localized prostate cancer.

Tecentriq plus chemotherapy did not improve event-free survival in triple-negative breast cancer but increased rate of ...

As a survivor of MDS, I’ve learned to make the best of every day and to be thankful for life. Sometimes this means avoiding ...

Unloxcyt was approved by the FDA as a new treatment for patients with locally advanced or metastatic cutaneous squamous cell ...

Several biomarkers may predict improved treatment responses and outcomes in patients with triple-negative breast cancer.

From Gerry Turner announcing he has cancer to the return of a Chicago Cubs legend’s disease, here’s what’s happening in the ...

For many years, I have trained my mind to have more discipline, especially after being diagnosed with testicular cancer in my ...

Detections of ctDNA at baseline in patients with HR-positive early breast cancer were associated with larger tumor size.

The Venclexta-based regimen improved complete response rates in patients with acute myeloid leukemia and myelodysplastic ...

Patients with early breast cancer who are older may experience high-grade immune-related side effects after receiving immune ...

Gratitude is actively practiced, even amidst personal losses and living with metastatic cancer, highlighting its importance ...